I'm LongbridgeAI, I can summarize articles.Red Cat (RCAT) fell 11.75% this week to $8.49, underperforming the S&P 500’s +0.49% gain by roughly 12.24 percentage points. The stock opened Monday at $9.36, slid to $8.78 intraday, then chopped between $8.93 and $9.28 over the next three sessions before Friday’s push down to $8.45, leaving it near the week’s low. Weekly amplitude was 10.47%, with trading volume well below its median level.
The Week
Red Cat (RCAT) fell 11.75% this week to $8.49, underperforming the S&P 500’s +0.49% gain by roughly 12.24 percentage points. The stock opened Monday at $9.36, slid to $8.78 intraday, then chopped between $8.93 and $9.28 over the next three sessions before Friday’s push down to $8.45, leaving it near the week’s low. Weekly amplitude was 10.47%, with trading volume well below its median level.
Key Events
No company filings or material announcements landed this week. The news flow was mostly sector-level: two reports on Tuesday covered AI infrastructure spillover and grouped RCAT among smaller names drawing attention; a Thursday piece asked whether the Blue Ops-Havoc tie-up is quietly reframing Red Cat’s defence autonomy strategy, making it the most directly relevant story to the business; a Friday market update noted a 3.9% intraday jump that faded by the close, suggesting the partnership news did not generate sustained price support.
Analyst Ratings
Of the 6 covering institutions, 1 rates RCAT overweight and 5 rate it buy, with no hold, underweight or sell ratings. Consensus stands at strong buy, with a target price of $18.33, about 115.94% above the latest $8.49 close. Targets range from $15.00 to $25.00, showing wide dispersion but all sitting well above spot. Within the aerospace and defence industry, RCAT ranks 50th out of 84 covered names, in the lower-middle tier.
The Week Ahead
The macro calendar turns to the Dallas Fed manufacturing activity index on Monday 31 August, followed on Tuesday 1 September by ISM manufacturing PMI and JOLTS job openings, where the prior reading was 7.359m and consensus expects 7.3m. For a small-cap defence name like RCAT, manufacturing surveys and labour-market data may influence risk appetite and how money rotates among smaller stocks. The Blue Ops-Havoc reporting also leaves open whether more details surface in the coming week.
In Short
RCAT posted a double-digit decline this week without any major company announcements, even as consensus remains at strong buy and the target price sits more than 100% above spot. The latest session’s flows showed large-lot money as a net seller while small and medium orders turned net buyers, setting up a tension between institutional ratings and short-term money direction. The key questions are whether the Havoc-related autonomy work firms up, whether thinning volume reverses, and how the macro data shapes relative performance for smaller names.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.